Enantioselective metabolism and cytotoxicity of R-ifosfamide and S-ifosfamide by tumor cell-expressed cytochromes P450.

scientific article

Enantioselective metabolism and cytotoxicity of R-ifosfamide and S-ifosfamide by tumor cell-expressed cytochromes P450. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1124/DMD.105.004788
P8608Fatcat IDrelease_odckhoglg5c5rkad7xiiwfa3ua
P698PubMed publication ID15919850

P50authorDavid J. WaxmanQ30506493
P2093author name stringChong-Sheng Chen
Youssef Jounaidi
P433issue9
P921main subjectcytotoxicityQ246181
enantioselectivityQ1339952
P304page(s)1261-1267
P577publication date2005-05-26
P1433published inDrug Metabolism and DispositionQ1261140
P1476titleEnantioselective metabolism and cytotoxicity of R-ifosfamide and S-ifosfamide by tumor cell-expressed cytochromes P450.
P478volume33

Reverse relations

cites work (P2860)
Q91717495Antineoplastic Agents: Environmental Prevalence and Adverse Outcomes in Aquatic Organisms
Q36305439Cancer treatment and pharmacogenetics of cytochrome P450 enzymes
Q24298102Colorectal cancer-specific cytochrome P450 2W1: intracellular localization, glycosylation, and catalytic activity
Q39691802Comparison of the novel HK-2 human renal proximal tubular cell line with the standard LLC-PK1 cell line in studying drug-induced nephrotoxicity
Q48199323Computationally Assessing the Bioactivation of Drugs by N-Dealkylation.
Q30520640Contributions of human enzymes in carcinogen metabolism
Q36154879Enantioselective liquid chromatography-mass spectrometry assay for the determination of ifosfamide and identification of the N-dechloroethylated metabolites of ifosfamide in human plasma.
Q37288782Encephalopathy after high-dose Ifosfamide: a retrospective cohort study and review of the literature
Q28749176Engineering cytochrome P450 biocatalysts for biotechnology, medicine and bioremediation
Q37037051Enhancement of intratumoral cyclophosphamide pharmacokinetics and antitumor activity in a P450 2B11-based cancer gene therapy model
Q39064497Enzyme/Prodrug Systems for Cancer Gene Therapy.
Q47836150Establishment and assessment of a novel in vitro bio-PK/PD system in predicting the in vivo pharmacokinetics and pharmacodynamics of cyclophosphamide
Q36101917Metronomic cyclophosphamide activation of anti-tumor immunity: tumor model, mouse host, and drug schedule dependence of gene responses and their upstream regulators
Q37402750MicroRNAs regulate CYP3A4 expression via direct and indirect targeting
Q34113899Oxazaphosphorines: new therapeutic strategies for an old class of drugs
Q39916257Potentiation of methoxymorpholinyl doxorubicin antitumor activity by P450 3A4 gene transfer
Q97074138Prediction and Characterization of CYP3A4-mediated Metabolisms of Azole Fungicides: an Application of the Fused-grid Template* system
Q35095165Prodrugs for improving tumor targetability and efficiency.
Q51147639Screening for biologically annotated drugs that trigger triacylglycerol accumulation in the diatom Phaeodactylum.
Q49538988Significance and challenges of stereoselectivity assessing methods in drug metabolism
Q47594127Stereochemical considerations in pharmacokinetic processes of representative antineoplastic agents
Q36788391Stereoselectivity in drug metabolism
Q40253486Stereoselectivity in metabolism of ifosfamide by CYP3A4 and CYP2B6.

Search more.